Alberta Childrens Hospital

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Epilepsy2 trials
• Myasthenia gravis2 trials
• ANCA-associated vasculitis1 trial
• Duchenne muscular dystrophy1 trial

Phase

• Phase 34 trials
• Phase 2/32 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• argenx2 trials
• Takeda2 trials
• Amgen1 trial
• Sarepta Therapeutics, Inc.1 trial

Running trials

• Active, not recruiting

  Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

  NCT06321601· Phase 3· Amgen· Source

• Enrolling by invitation

  Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

  NCT05374590· Phase 2/3· argenx· Source

• Active, not recruiting

  Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

  NCT04833894· Phase 2/3· argenx· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myasthenia gravis1 recruiting

Closed trials

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

  NCT04940624· Phase 3· Takeda· Source

• Completed

  Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT02500381· Phase 3· Sarepta Therapeutics, Inc.· Source